- Guselkumab - the first selective IL-23 inhibitor for the treatment of psoriatic arthritis2023 | First Faculty of Medicine
- Guselkumab in the treatment of psoriatic arthritis2021 | Publication without faculty affiliation
- A female patient with severe psoriasis and an oncological illness, treated with guselkumab2023 | Third Faculty of Medicine
- Photoprotection in drug-induced photosensitivity2020 | Third Faculty of Medicine
- Guselkumab - první inhibitor IL-23 v léčbě psoriázy2019 | Third Faculty of Medicine
- Long-Term Efficacy, Safety, and Drug Survival of Guselkumab in Patients with Psoriasis: Real-World Data from the Czech Republic BIOREP Registry2023 | Third Faculty of Medicine, First Faculty of Medicine
- Current Approach to Modern Treatment of Psoriasis - Updated Guidelines of ČDS JEP for Targeted Treatment of Severe Chronic Psoriasis2019 | Third Faculty of Medicine, Faculty of Medicine in Pilsen, First Faculty of Medicine
- Risankizumab in first-line treatment of psoriasis2022 | Faculty of Medicine in Pilsen
- Drug Survival of Interleukin (IL)-17 and IL-23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi-country, Multicentric Cohort Study2022 | Third Faculty of Medicine
- Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study2021 | Third Faculty of Medicine
- Successful treatment of recalcitrant hidradenitis suppurativa with risankizumab after failure of anti-tumour necrosis factor alpha2021 | Third Faculty of Medicine